JP7256823B2 - メチル修飾酵素のモジュレーター、その組成物および使用 - Google Patents

メチル修飾酵素のモジュレーター、その組成物および使用 Download PDF

Info

Publication number
JP7256823B2
JP7256823B2 JP2020557175A JP2020557175A JP7256823B2 JP 7256823 B2 JP7256823 B2 JP 7256823B2 JP 2020557175 A JP2020557175 A JP 2020557175A JP 2020557175 A JP2020557175 A JP 2020557175A JP 7256823 B2 JP7256823 B2 JP 7256823B2
Authority
JP
Japan
Prior art keywords
alkyl
halo
cancer
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020557175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522166A5 (https=
JP2021522166A (ja
JPWO2019204490A5 (https=
Inventor
コテ，アレクサンドル
ゲーリング，ビクター・エス
カンナ，アビナッシュ
モアンヌ，リュディビーヌ
スタッキー，ジェイコブ・アイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Constellation Pharmaceuticals Inc
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of JP2021522166A publication Critical patent/JP2021522166A/ja
Publication of JP2021522166A5 publication Critical patent/JP2021522166A5/ja
Publication of JPWO2019204490A5 publication Critical patent/JPWO2019204490A5/ja
Priority to JP2023057753A priority Critical patent/JP2023082132A/ja
Application granted granted Critical
Publication of JP7256823B2 publication Critical patent/JP7256823B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
JP2020557175A 2018-04-18 2019-04-17 メチル修飾酵素のモジュレーター、その組成物および使用 Active JP7256823B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023057753A JP2023082132A (ja) 2018-04-18 2023-03-31 メチル修飾酵素のモジュレーター、その組成物および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659408P 2018-04-18 2018-04-18
US62/659,408 2018-04-18
PCT/US2019/027932 WO2019204490A1 (en) 2018-04-18 2019-04-17 Modulators of methyl modifying enzymes, compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023057753A Division JP2023082132A (ja) 2018-04-18 2023-03-31 メチル修飾酵素のモジュレーター、その組成物および使用

Publications (4)

Publication Number Publication Date
JP2021522166A JP2021522166A (ja) 2021-08-30
JP2021522166A5 JP2021522166A5 (https=) 2022-03-24
JPWO2019204490A5 JPWO2019204490A5 (https=) 2022-03-24
JP7256823B2 true JP7256823B2 (ja) 2023-04-12

Family

ID=66429588

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020557175A Active JP7256823B2 (ja) 2018-04-18 2019-04-17 メチル修飾酵素のモジュレーター、その組成物および使用
JP2023057753A Pending JP2023082132A (ja) 2018-04-18 2023-03-31 メチル修飾酵素のモジュレーター、その組成物および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023057753A Pending JP2023082132A (ja) 2018-04-18 2023-03-31 メチル修飾酵素のモジュレーター、その組成物および使用

Country Status (34)

Country Link
US (2) US10689371B2 (https=)
EP (2) EP4421072A1 (https=)
JP (2) JP7256823B2 (https=)
KR (2) KR20250073166A (https=)
CN (2) CN119954787A (https=)
AR (1) AR114793A1 (https=)
AU (1) AU2019255310B2 (https=)
BR (1) BR112020021194A2 (https=)
CL (1) CL2020002698A1 (https=)
CO (1) CO2020014217A2 (https=)
CR (1) CR20200553A (https=)
DK (1) DK3781561T3 (https=)
EA (1) EA202092490A1 (https=)
ES (1) ES2983344T3 (https=)
FI (1) FI3781561T3 (https=)
HR (1) HRP20240793T1 (https=)
HU (1) HUE066783T2 (https=)
IL (1) IL278013B2 (https=)
LT (1) LT3781561T (https=)
MA (1) MA52288B1 (https=)
MD (1) MD3781561T2 (https=)
MX (1) MX2020010999A (https=)
MY (1) MY208662A (https=)
PE (1) PE20201448A1 (https=)
PH (1) PH12020551578A1 (https=)
PL (1) PL3781561T3 (https=)
PT (1) PT3781561T (https=)
RS (1) RS65621B1 (https=)
SG (1) SG11202009438UA (https=)
SI (1) SI3781561T1 (https=)
SM (1) SMT202400233T1 (https=)
TW (1) TWI828677B (https=)
UA (1) UA127357C2 (https=)
WO (1) WO2019204490A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
KR102689665B1 (ko) 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
WO2021016414A1 (en) * 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
WO2021016409A1 (en) * 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Ezh2 inhibition in combination therapies for the treatment of cancers
US20230365541A1 (en) * 2020-03-13 2023-11-16 Haisco Pharmaceuticals Pte. Ltd. Inhibitor of enhancer of zeste homologue 2, and use thereof
CN113666920B (zh) * 2020-04-14 2025-10-03 浙江华海药业股份有限公司 苯并恶唑类化合物制备方法及其在医药领域的应用
WO2022009911A1 (ja) * 2020-07-08 2022-01-13 第一三共株式会社 １，３－ベンゾジオキソール誘導体の製造方法
IL303025A (en) * 2020-11-18 2023-07-01 Constellation Pharmaceuticals Inc EZH2 inhibition therapies for prostate cancer with androgen receptor mutation
KR102872076B1 (ko) 2021-01-11 2025-10-15 주식회사 엘지에너지솔루션 전극 슬러리의 유량 제어가 가능한 전극 슬러리 코팅 시스템 및 이를 이용한 전극 슬러리 코팅 방법
CN118541367A (zh) * 2022-01-14 2024-08-23 同和药品株式会社 1,3-苯并间二氧杂环戊烯衍生物化合物及包含该化合物的药物组合物
CN116496263A (zh) * 2022-01-27 2023-07-28 江苏天士力帝益药业有限公司 Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用
WO2023217018A1 (zh) * 2022-05-07 2023-11-16 贝达药业股份有限公司 Ezh2抑制剂及其在医药上的应用
EP4536658A1 (en) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
IL318787A (en) 2022-08-17 2025-04-01 Incyte Corp Treatment including ANTI-CD19 antibodies and EZH2 modulators
CN121712510A (zh) * 2023-07-06 2026-03-20 同和药品株式会社 包含1,3-苯并间二氧杂环戊烯衍生物化合物的药物组合物
TW202542136A (zh) * 2023-12-15 2025-11-01 大陸商格物生物技術（江蘇）有限公司 １，３－苯并二氧雜環戊烯衍生物以及其用途
WO2026077358A1 (en) * 2024-10-07 2026-04-16 Constellation Pharmaceuticals, Inc. Solid forms and salts of 7-chloro-2- (4- (3-methoxyazetidin-1-yl) cyclohexyl) -2, 4-dimethyl-n- ( (6-methyl-4- (methylthio) -2-oxo-1, 2-dihydropyridin-3-yl) methyl) benzo [d] [1, 3] dioxole-5-carboxamide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506985A (ja) 2012-02-10 2015-03-05 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
WO2015141616A1 (ja) 2014-03-17 2015-09-24 第一三共株式会社 １，３－ベンゾジオキソール誘導体
CA3002436A1 (en) 2015-11-19 2017-05-26 Biao Lu Benzofuran derivative, preparation method thereof and use thereof in medicine

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317850A (ja) 1986-07-11 1988-01-25 Fuji Photo Film Co Ltd ３−フエノキシカテコ−ル類の製造方法
NZ231631A (en) 1988-12-08 1992-07-28 Duphar Int Res Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions
JPH02255674A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法
JPH02255673A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法
JPH02269352A (ja) 1989-04-10 1990-11-02 Fuji Photo Film Co Ltd 感光材料
JP2537682B2 (ja) 1989-04-21 1996-09-25 富士写真フイルム株式会社 ３―アリ―ルオキシカテコ―ル類の製造方法
US5296497A (en) 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
JPH03130280A (ja) 1989-10-17 1991-06-04 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法
JP2816492B2 (ja) 1990-05-23 1998-10-27 コニカ株式会社 ハロゲン化銀写真感光材料
JPH0446175A (ja) 1990-06-14 1992-02-17 Fuji Photo Film Co Ltd ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
WO1997026884A1 (en) 1996-01-29 1997-07-31 The Regents Of The University Of California Method for treating sexual dysfunctions
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
ATE317226T1 (de) 1997-10-27 2006-02-15 Cortex Pharma Inc Behandlung der schizophrenie mit ampakinen und neuroleptika
BR9914167B1 (pt) 1998-09-29 2011-03-09 compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
EP1384713B1 (en) * 1998-12-23 2008-10-15 SmithKline Beecham Corporation 4-amino-azepan-3-one derivatives as protease inhibitors
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
CA2419301C (en) 2000-08-21 2009-12-08 Astrazeneca Ab Quinazoline derivatives
AU2001281246A1 (en) 2000-08-23 2002-03-04 The Procter And Gamble Company Benzimidazoles and analogues and their use as neutrophil inhibitors
PT1334091E (pt) 2000-08-24 2013-01-07 Univ Pittsburgh Derivados de tioflavina e seu uso no diagnóstico e terapia da doença de alzheimer
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
WO2002074307A1 (en) 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
ATE348097T1 (de) 2001-04-09 2007-01-15 Chiron Corp Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
EP1503986B1 (en) 2001-12-21 2015-09-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CN1646119A (zh) 2002-04-09 2005-07-27 诺沃根研究有限公司 涉及异黄－3－烯和异黄烷结构的治疗方法和组合物
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
US20060153782A1 (en) 2002-09-23 2006-07-13 Novogen Research Pty Ltd Skin photoageing and actinic damage treatment
DE602004022170D1 (de) 2003-07-28 2009-09-03 Merck Serono Sa Coinsins 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
JP2007511542A (ja) 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
CA2542351A1 (en) 2003-11-19 2005-06-02 Novogen Research Pty Ltd. Combinational radiotherapy and chemotherapy compositions and methods
US7432377B2 (en) 2004-01-16 2008-10-07 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
AU2005233125A1 (en) 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
JP4604086B2 (ja) 2004-05-07 2010-12-22 エグゼリクシス， インコーポレイテッド Ｒａｆモジュレーターおよびその使用方法
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
AU2005293556A1 (en) 2004-10-12 2006-04-20 Merck Serono Sa PI3 Kinase gamma inhibitors for the treatment of anaemia
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP2006145294A (ja) 2004-11-17 2006-06-08 Univ Nagoya 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
PL1859793T3 (pl) 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
EP1893605A2 (en) 2005-03-31 2008-03-05 AstraZeneca AB Saminopyrimidine derivates with tie2 inhibiting activity
EP1869014A2 (en) 2005-04-08 2007-12-26 Bayer Pharmaceuticals Corporation Pyrimidine derivatives
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
CA2608394A1 (en) 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
WO2006129609A1 (ja) 2005-05-30 2006-12-07 Shionogi & Co., Ltd. ２－ナフチルイミノ－５，５－ジ置換－１，３－チアジン誘導体
AU2006252768A1 (en) 2005-06-02 2006-12-07 Bayer Cropscience Ag Phenylalkyl substituted heteroaryl devivatives
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
US20070093455A1 (en) 2005-07-21 2007-04-26 Paul Abato 10-substituted tetracyclines and methods of use thereof
CN101277700B (zh) 2005-08-04 2013-02-20 詹森药业有限公司 作为5-羟色胺受体调节剂的嘧啶化合物
WO2007020936A1 (ja) 2005-08-17 2007-02-22 Daiichi Sankyo Company, Limited 抗真菌作用二環性複素環化合物
WO2007081630A2 (en) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Substituted pyrimidinyl kinase inhibitors
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
BRPI0709110A2 (pt) 2006-03-23 2011-06-28 Prolysis Ltd agentes antibacterianos
US8158619B2 (en) 2006-05-30 2012-04-17 Neurosearch A/S 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use
US20100035877A1 (en) 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
WO2008029168A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
AU2007314141A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
RU2333211C1 (ru) 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
US9096546B2 (en) 2007-05-10 2015-08-04 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0704074B8 (pt) 2007-08-29 2021-05-25 Univ Estadual Paulista Julio De Mesquita Filho Unesp derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
ES2630406T3 (es) 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
SG2014015085A (en) 2008-04-16 2014-06-27 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
NZ590005A (en) 2008-06-23 2012-06-29 Janssen Pharmaceutica Nv Piperidyl acrylamide antogonists of ccr2
WO2010019772A2 (en) 2008-08-14 2010-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oxadiazole-2-oxides as antischistosomal agents
JP2010254629A (ja) 2009-04-27 2010-11-11 Bayer Cropscience Ag 光学活性アゾリン誘導体
AR076928A1 (es) 2009-05-28 2011-07-20 Otsuka Pharma Co Ltd Derivados de 3h-pirido[4, 3-d]pirimidin-4-ona, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el estres.
CA2767474A1 (en) 2009-07-10 2011-01-13 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
RU2417082C2 (ru) 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
WO2011084657A1 (en) 2009-12-17 2011-07-14 The Lubrizol Corporation Lubricating composition containing an aromatic compound
KR101781789B1 (ko) 2010-01-27 2017-09-26 에이비 파르마 리미티드. C형 간염 바이러스 억제제로 사용되는 다환 헤테로사이클릭 화합물
CN101851218B (zh) 2010-04-27 2014-10-15 沈阳药科大学 4,5-二取代芳基异硒唑类衍生物及其用途
EP2580215A4 (en) 2010-06-10 2014-01-15 Afraxis Holdings Inc 8- (HETEROCYCYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
WO2012013725A1 (en) 2010-07-28 2012-02-02 Medizinische Universität Wien Vinylogous chalcone derivatives and their medical use
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
TW201225957A (en) 2010-09-17 2012-07-01 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitor
WO2012045196A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Phosphoglycerate kinase inhibitors
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
WO2013025484A1 (en) 2011-08-12 2013-02-21 Lapchak Paul A Polyphenol analogs to treat ischemia
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013065835A1 (ja) 2011-11-04 2013-05-10 味の素株式会社 糖尿病治療用医薬組成物
EP2828245A1 (en) 2012-03-21 2015-01-28 Rutgers, The State University of New Jersey Antimicrobial agents
RU2509770C2 (ru) 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
MX2015002555A (es) 2012-08-30 2015-06-23 Nippon Shinyaku Co Ltd Derivado de piridina y medicina.
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
HK1220184A1 (zh) 2013-03-13 2017-04-28 Boston Biomedical, Inc. 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
WO2014177464A2 (en) 2013-04-30 2014-11-06 Heinrich-Heine-Universität Düsseldorf Inhibitors of nhr2 and/or runx1/eto-tetramerization
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
CN107311992B (zh) 2013-09-09 2020-08-18 上海研健新药研发有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
WO2015069110A1 (en) 2013-11-07 2015-05-14 Aapa B.V. Multiple d2 a(nta)gonists/h3 antagonists for treatment of cns-related disorders
EP3157915B1 (en) 2014-06-17 2019-02-27 Pfizer Inc Substituted dihydroisoquinolinone compounds
WO2016038540A1 (en) 2014-09-11 2016-03-17 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
WO2016130396A1 (en) * 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
BR112018001688B1 (pt) 2015-07-30 2023-05-02 Daiichi Sankyo Company, Limited Uso de um composto
US20170197947A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
CA3012133A1 (en) 2016-02-09 2017-08-17 Inventisbio Inc. Inhibitor of indoleamine-2,3-dioxygenase (ido)
US20170355708A1 (en) * 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
CN106727549A (zh) 2016-11-26 2017-05-31 李�荣 一种治疗抑郁症的药物
JP7125353B2 (ja) 2017-01-19 2022-08-24 第一三共株式会社 Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
WO2018170513A1 (en) 2017-03-17 2018-09-20 Cornell University Compounds and compositions for inhibition and elimination of zika infection and uses for same
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US12171755B2 (en) 2017-10-25 2024-12-24 Children's Medical Center Corporation PAPD5 inhibitors and methods of use thereof
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
JP2021035913A (ja) 2017-12-21 2021-03-04 石原産業株式会社 Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤
CA3125731A1 (en) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer
JP2019168611A (ja) 2018-03-23 2019-10-03 株式会社Adeka 光学フィルタ
US20210093591A1 (en) 2018-03-30 2021-04-01 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Methods for mitigating and preventing proteostasis-based injuries
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015506985A (ja) 2012-02-10 2015-03-05 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
WO2015141616A1 (ja) 2014-03-17 2015-09-24 第一三共株式会社 １，３－ベンゾジオキソール誘導体
CA3002436A1 (en) 2015-11-19 2017-05-26 Biao Lu Benzofuran derivative, preparation method thereof and use thereof in medicine

Also Published As

Publication number Publication date
IL278013B2 (en) 2024-01-01
US10689371B2 (en) 2020-06-23
MY208662A (en) 2025-05-22
US20200317651A1 (en) 2020-10-08
CO2020014217A2 (es) 2021-03-08
KR20250073166A (ko) 2025-05-27
CN119954787A (zh) 2025-05-09
AU2019255310B2 (en) 2022-11-24
HRP20240793T1 (hr) 2024-09-13
PH12020551578A1 (en) 2021-09-13
PT3781561T (pt) 2024-06-18
PE20201448A1 (es) 2020-12-10
EA202092490A1 (ru) 2020-12-23
KR102798145B1 (ko) 2025-04-22
AR114793A1 (es) 2020-10-14
BR112020021194A2 (pt) 2021-03-23
CL2020002698A1 (es) 2021-01-15
MA52288A (fr) 2021-04-07
US11274095B2 (en) 2022-03-15
EP4421072A1 (en) 2024-08-28
KR20210003160A (ko) 2021-01-11
US20240116905A1 (en) 2024-04-11
HUE066783T2 (hu) 2024-09-28
CR20200553A (es) 2021-04-08
TW202003505A (zh) 2020-01-16
FI3781561T3 (fi) 2024-06-13
MD3781561T2 (ro) 2025-02-28
CN111989325A (zh) 2020-11-24
AU2019255310A1 (en) 2020-10-15
WO2019204490A1 (en) 2019-10-24
RS65621B1 (sr) 2024-07-31
EP3781561A1 (en) 2021-02-24
SG11202009438UA (en) 2020-11-27
DK3781561T3 (da) 2024-06-17
IL278013A (en) 2020-11-30
MA52288B1 (fr) 2024-07-31
ES2983344T3 (es) 2024-10-22
UA127357C2 (uk) 2023-07-26
US20190322651A1 (en) 2019-10-24
EP3781561B1 (en) 2024-03-13
PL3781561T3 (pl) 2024-07-22
CA3098428A1 (en) 2019-10-24
SMT202400233T1 (it) 2024-07-09
JP2023082132A (ja) 2023-06-13
CN111989325B (zh) 2025-02-25
TWI828677B (zh) 2024-01-11
LT3781561T (lt) 2024-07-10
JP2021522166A (ja) 2021-08-30
SI3781561T1 (sl) 2024-08-30
MX2020010999A (es) 2021-01-20
IL278013B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
JP7256823B2 (ja) メチル修飾酵素のモジュレーター、その組成物および使用
EP3797108B1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
IL291413B2 (en) 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
EA035544B1 (ru) Производные тетрагидроизохинолина
JP2017527577A (ja) 置換ピロリジン化合物
JP2017526706A (ja) イソオキサゾールカルボキサミド化合物
JP2017527576A (ja) 置換シクロヘキシルアミン化合物
US12612390B2 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
CA3098428C (en) Modulators of methyl modifying enzymes, compositions and uses thereof
HK40115243A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
EA042914B1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
HK40046605A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
HK40046605B (en) Modulators of methyl modifying enzymes, compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220315

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230331

R150 Certificate of patent or registration of utility model

Ref document number: 7256823

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250